TORONTO & ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that new data providing further understanding on Cladribine Tablets as a potential new therapeutic option for relapsing forms of multiple sclerosis (MS) were presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN). Cladribine Tablets, EMD Serono’s proprietary investigational oral formulation of cladribine, is currently under regulatory review in a number of countries.
